April Journal-2009.p65 - Association of Biotechnology and Pharmacy

Current Trends in Biotechnology and Pharmacy
Vol. 3 (2) 219-224, April 2009. ISSN 0973-8916
222
a
c
b
BLR- and silymarin-treated groups exhibited lower
levels of marker enzymes as compared to CCl 4
-
treated group. The stabilization of marker enzyme
levels by BLR is a clear indication of the
improvement of the functional status of the liver
cells.
These findings can be further confirmed
with histopathological studies. The
histopathological examination clearly reveals that
the hepatic cells and central vein are near to
normal in BLR (400 mg/kg, p.o.) group in contrast
to group which received CCl 4
. Thus, BLR can
be considered to be an effective hepatoprotective
drug as it brings near to normalcy the damage
caused by CCl 4
to hepatic function. Hence this
drug can be used in polyherbal formulations to
provide a synergistic effect with other
hepatoprotective drugs and there by preventing
Thirupathi et al
e
d
Fig.1. (a). Section through the liver of normal rats showing
central vein and hepatocytes. (b). Section through the liver
of CCl 4
-treated rats showing central vein and hepatocytes.
Note the necrosis of hepatic cells and formation of vacuoles.
(c,d, e). Section through the liver of BLR-treated (100 mg/
kg, 400 mg/kg and Standard respectively) rats showing the
central vein (round marking) and hepatocytes.